CASE REPORT

Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

Semira Sheikh1 | Sepideh Mokhtari2 | Jeffrey A. Silverman3 | Kayla Reid4 | Rawan Faramand5 | Marco L. Davila6 | Norman Franke7 | Frederick L. Locke6 | Michael D. Jain6 | Daniel Wong8 | John G. Kuruvilla7

1 Division of Medical Oncology and Hematology, University Health Network, Toronto, Canada
2 Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida, USA
3 Department of Hematology, North York General Hospital, Toronto, Canada
4 Department of Hematology, Moffitt Cancer Center, Tampa, Florida, USA
5 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA
6 Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA
7 Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
8 Department of Neurology, North York General Hospital, Toronto, Canada

Correspondence
Semira Sheikh, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C1, Canada.
Email: semirasheikh@gmail.com
John G. Kuruvilla, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
Email: John.Kuruvilla@uhn.ca

KEYWORDS
CAR T cell therapy, ICANS, neurotoxicity, transverse myelitis

Chimeric antigen receptor (CAR) T cell therapy has transformed the care of patients with relapsed/refractory large B cell lymphoma and is associated with unique toxicities, in particular cytokine release syndrome (CRS) and neurotoxicity/immune effector cell-associated encephalopathy syndrome (ICANS) [1–3]. The pathophysiology of neurotoxicity with CAR T cell therapy is not well understood, and a spectrum of presentations is increasingly recognized. Here we report the case of a patient who developed transverse myelitis after receiving CAR T cell therapy.

A 28-year old woman with refractory primary mediastinal B cell lymphoma was referred for standard of care (SOC) CAR T cell therapy after receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, radiation, and GDP (gemcitabine, dexamethasone, and cisplatin) salvage chemotherapy. Due to tumor burden with extensive abdominal involvement, she received bridging therapy with pembrolizumab, dexamethasone, and radiation to the right kidney (see treatment summary, Figure 1A). During lymphodepletion, the patient developed high fevers of up to 40°C, with groundglass opacities on the CT thorax. No infectious etiology was determined; full septic workup, bronchoscopy, and COVID19 testing were negative.

The patient proceeded with Axi-cel infusion. Baseline inflammatory markers on D 0 were elevated (Table 1, panel A). From D +1 to D +4, the patient continued to spike fevers >38°C, attributed to Grade 1 CRS (American society for transplantation and cellular therapy criteria). On D +4, the patient became nonverbal, unable to answer questions or follow commands, with myoclonic jerks but no focal motor or sensory symptoms. Her immune effector cell associated encephalopathy score was 0/10 (Grade 4 ICANS). Grade 4 hepatotoxicity (CTCAE v5.0) developed on D +5 (Figure 1B). There were no acute findings on brain MRI (magnetic resonance imaging), and an EEG showed generalized rhythmic delta activity with intermittent generalized periodic discharges; an extremely elevated protein level on lumbar puncture (LP) was consistent with neurotoxicity (Table 1, panel B). The patient...
received tocilizumab x 1 on D+4 and a dexamethasone taper to D+18 (Figure 1B). Fever and hepatotoxicity resolved from D+5; her neurological status returned to baseline on D+13.

At routine outpatient follow-up on D+27, the patient reported ascending paresthesiae to the chest area. Neurological examination showed hyperreflexia, diminished sensation to pinprick, vibration, and temperature in both lower extremities, impaired proprioception in the toes, and unsteady gait; there was no motor weakness.

Small bilateral subdural collections thought to be subacute in the setting of a chronically low platelet count were demonstrated on MRI brain, but, otherwise, there were no acute changes. MRI of the spine showed a subtle signal abnormality from T1–T7 within the dorsal central cord, concerning for transverse myelitis. A D+30 response assessment PET scan demonstrated a complete metabolic response from lymphoma (Figure 3).

The patient received treatment with steroids and intravenous immunoglobulin (IVIG) for presumed transverse myelitis but returned on D+33 with worsening ascending numbness, bilateral leg weakness, and urinary retention (Figure 1). On examination, there was a T4 sensory level to pinprick, bilateral leg weakness (4/5 in a pyramidal distribution), and extensor plantar responses. MRI of the spine showed an abnormal signal in the cord from T1–T7, in keeping with transverse myelitis (Figure 2). Pulsed IV steroid was given; the patient was discharged on a prednisone tapering schedule but returned on D+49 with paraplegia. Repeat LP was unremarkable (Table 1, panel B), and MRI of the spine demonstrated persistent and increased abnormal signal intensity in the central cord and posterior columns, unchanged in size. An extensive workup for autoimmune and infectious causes of transverse myelitis was negative (Table 1, panel C). The patient received further steroid therapy and plasma exchange (PLEX), with no significant improvement in symptoms. Follow-up MRI (D+65) showed progression of myelitis with extension of signal change from C7 to T7 with enhancement. Further steroid therapy with a slow taper and IVIG were given.

Over the next 4 months, the patient regained some motor strength in the lower limbs (2/5 hip flexion, 4/5 plantar flexion) and reported improvement in sensory symptoms (pinprick sensation to the level of the hips bilaterally). Follow-up imaging of the spine on D+208 showed significant improvement in cord signal change from T1–T6 with resolution of enhancement (Figure 2). A positron emission tomography (PET) scan on D+104 showed ongoing complete metabolic remission from lymphoma (Deauville score 2).

We describe an unusual case of transverse myelitis after treatment with anti-CD19 CAR T cell therapy, with a relapsing/remitting course over a 5-month period before stabilization and improvement of symptoms. Treatment with CAR T cells was preceded by the administration

| FIGURE 1 | Treatment course. (A) Timeline pre-bridging and lymphodepletion (B) Timeline lymphodepletion to D+27 (C) Timeline D+30 to D+208 | Day | D-43 | D-28 | D-27 to -23 | D-22 to -16 |
| --- | --- | --- | --- | --- | --- |
| **Event** | Bridging #1 | Apheresis | Bridging #2 | Bridging/Debugging |
| **Treatment** | Pembro #1 | Dexamethasone 40mg od x 4 days | Radiation to right kidney |
| **FIGURE 1** | Treatment course. (A) Timeline pre-bridging and lymphodepletion (B) Timeline lymphodepletion to D+27 (C) Timeline D+30 to D+208 | Day | D-6 to -3 | D 0 | D+4 to +18 | D+27 |
| **Event** | Lymphodepletion | Axel infusion | CRS Grade 1 | ICANS Grade 4 | Dexamethasone t x1 |
| **Treatment** | Cy 500mg/m² x3 days | Flu 24mg/m² (dose reduced for GFR) x3 days | IV Rocephin/ Azithromycin | Tocilizumab x1 | Dexamethasone 10mg IV 6hrly x 4 days with taper |
| **FIGURE 1** | Treatment course. (A) Timeline pre-bridging and lymphodepletion (B) Timeline lymphodepletion to D+27 (C) Timeline D+30 to D+208 | Day | D+30 to +33 | D+49 | D+65 to +96 | D+97 to +208 |
| **Event** | Paresthesiae | Motor weakness | Motor weakness progressing to paraplegia | Stable symptoms | Progressive MRI findings | Slow improvement in motor strength | Improved MRI appearances | PET scan: ongoing CMR |
| **Treatment** | Solumedrol 1g/d x3 days | Steroid taper | Solumedrol 1g/d x2 days | PLEX x7 days | Solumedrol 1g/d x5d | Solumedrol 1g/d x2d |

We describe an unusual case of transverse myelitis after treatment with anti-CD19 CAR T cell therapy, with a relapsing/remitting course over a 5-month period before stabilization and improvement of symptoms. Treatment with CAR T cells was preceded by the administration

| FIGURE 1 | Treatment course. (A) Timeline pre-bridging and lymphodepletion (B) Timeline lymphodepletion to D+27 (C) Timeline D+30 to D+208 | Day | D-43 | D-28 | D-27 to -23 | D-22 to -16 |
| --- | --- | --- | --- | --- | --- |
| **Event** | Bridging #1 | Apheresis | Bridging #2 | Bridging/Debugging |
| **Treatment** | Pembro #1 | Dexamethasone 40mg od x 4 days | Radiation to right kidney |

We describe an unusual case of transverse myelitis after treatment with anti-CD19 CAR T cell therapy, with a relapsing/remitting course over a 5-month period before stabilization and improvement of symptoms. Treatment with CAR T cells was preceded by the administration
TABLE 1  Summary of the patient workup for inflammatory and infectious causes

| (A) | Marker | CRP | Ferritin | IFN-γ | IL-15 | IL-2 | IL-6 | Ang-1 | Ang-2 | Ang2/Ang1 | GM-CSF | TNF-α |
|-----|--------|-----|----------|-------|-------|------|------|-------|-------|-----------|--------|-------|
| Level (range) | 310 mg/L (< 10 mg/L) | 989 ng/L (30 - 300 ng/L) | 11.9 pg/mL (0.544 - 2.72) | 4.64 pg/mL (1.40 - 3.36) | 0.802 pg/mL (0.54 - 2050) | 16.8 pg/mL (0.762 - 6.38) | 25703 pg/mL (17,820 - 75,300) | 5975 pg/mL (1096 - 1685) | 0.23 | 1.08 pg/mL (ND - 4.98) | 87 pg/mL (4.05 - 8.34) |

| (B) | CSF | Day+5 | Day+49 |
|-----|-----|-------|--------|
| Colour | clear | clear | |
| WBC count | 8 | 3 | |
| Protein (g/L) | 4.45 | 0.38 | |
| Albumin (g/L) | 2.41 | NA | |
| Glucose (mmol/L) | 4.7 | 2.8 | |
| Myelin basic protein (ng/mL) | 58.8 | NA | |
| IgG synthesis rate (mg/d) | 30.5 | NA | |
| Oligoclonal bands | neg | NA | |
| Culture | neg | | |

| (C) | Negative TM work up | Infectious | Autoimmune |
|-----|---------------------|------------|------------|
| Enterovirus | | Anti-Tr (DNER) | |
| West Nile virus | | Anti-GAD65 | |
| Herpes simplex virus 1 & 2 | | Anti-Zic4 | |
| Varicella zoster | | Anti-Hu | |
| CMV | | Anti-Yo | |
| EBV | | Anti-Ri | |
| HHV 6, HHV8 | | Anti-Ma:Ta | |
| JC virus | | Anti-CV2 | |
| VDRL | | Anti-amphysin | |
| Lyme disease | | Anti-MOG | |
| Acid fast bacilli | | Anti-aquaporin | |
| Fungal culture | | RhF | |
| Cryptococcus | | ANA | |
| HIV | | ANCA | |
| HTLV 1 and 2 | | Lupus anticoagulant, anti-cardiolipin | |

of a checkpoint inhibitor targeting PD-1 due to efficacy in primary mediastinal B cell lymphoma [12]. Checkpoint inhibitor treatment itself can be associated with neurological complications but can be combined with CAR T cell therapy with a manageable safety profile [13–15].

Neurotoxicity following CAR T cell therapy is common but usually self-limited and reversible. Pivotal studies of CAR T cell therapy in lymphoma reported ICANS Grade ≥3 in 10–28% of patients, although grading schemes have differed [1–3]. A biphasic pattern has been described, with the first phase often occurring in the context of CRS, and a second delayed phase of presentation in approximately 10% of patients [4–7]. Clinical manifestations of neurotoxicity can vary widely, ranging from headache to encephalopathy, seizures, and cerebral edema. Atypical presentations, including acute leukoencephalopathy and transverse myelitis, have also been reported [8, 16].

The pathophysiology driving neurotoxicity is not well understood. Several reports have implicated endothelial activation and blood-brain-barrier (BBB) disruption which may facilitate the influx of cytokines, recruitment of monocytes, and activation of macrophages, but elevated levels of the excitatory N-methyl-D-aspartate receptor agonists glutamate and quinolinic acid have also been described [6, 9, 17].
Risk factors associated with the development of neurotoxicity include patient-related factors such as younger age, higher tumor burden, and a history of early and/or high-grade CRS, as well as product-related characteristics such as CAR design and choice of lymphodepletion regimen. Our patient presented with multiple risk factors including young age, extensive tumor burden at relapse, and she received a CD28-costimulated CAR T cell product. She had a particularly high baseline ANG2 known to be associated with increased endothelial cell activation and posited to represent BBB permeability. An association between baseline IL-6, ANG2, ANG2/ANG1, and ferritin, with subsequent severe neurotoxicity after CAR T cell therapy has been described. Indeed, this patient developed evidence of severe BBB permeability after CAR T infusion with a high cerebrospinal fluid (CSF) protein level.

One limitation of this case report is that in the SOC setting CAR T cells are not routinely quantified or phenotyped, and, therefore, we could not determine if there were any CAR T cell characteristics that differed in this case, and neither was it possible to determine the presence of CAR T cells in the CSF. The patients who developed leukoencephalopathy in the case report from ZUMA-1, for example, were found to have a massive expansion of peripheral CAR T cells and prominent features of BBB disruption.

Interestingly, it is also unclear whether any of the treatments pursued (pulsed corticosteroids, PLEX, IVIG) changed the disease course or whether time alone leads to disease improvement in such cases. Rituximab was not administered as CD19 CAR T cell therapy strongly depletes B cells, and additional B cell depletion was considered unlikely to be of benefit.

As a relatively new technology, rare and unexpected side effects may occur in patients receiving CAR T cell therapy. Reporting and collection of such cases will help to increase awareness of rare presentations and advance the expertise in managing these challenging cases.

ACKNOWLEDGMENTS
We thank the patient, her caregivers, and the health care providers.

CONFLICT OF INTEREST
SS, SM, JAS, KR, NF, DW: No disclosures. RF: Research funding from Novartis and Kite. MLD: Research funding from Celgene, Novartis, Kite, and Atara; other financial support from Novartis, Precision Biosciences, Celyad, Bellicum, and GlaxoSmithKline; stock options from Precision Biosciences, Adaptive Biotechnologies, and Anixa Biosciences. FLL: Scientific advisory role with Kite, a Gilead Company, Novartis, Celgene/Bristol-Myers Squibb, GammaDelta Therapeutics, Wugen, Amgen, Calibr, and Allogene; consultant with grant options for Cellular Biomedicine Group, Inc.; research support from Kite.
a Gilead Company. MDJ: Consultancy/advisory role for Kite/Gilead, Novartis, Takeda, and BMS. JGK: Consultant or advisory role for Abbvie, BMS, Gilead, Karyopharm, Merck, Roche, Seattle Genetics; honoraria from Amgen, Antengene, Astra Zeneca, BMS, Gilead, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Genetics, TG Therapeutics; research funding from Canadian Cancer Society, Leukemia and Lymphoma Society Canada, Princess Margaret Cancer Foundation, Janssen, Roche, Astra Zeneca; other remuneration from Karyopharm (DSMB).

AUTHOR CONTRIBUTIONS
KR and RF performed cytokine and data analyses and reviewed the manuscript; SS, MDJ, DW, and JGK analyzed data and wrote and edited the manuscript; JAS, MLD, NF, and FLL critically reviewed and edited the manuscript; JS, ML, and RLF performed cytokine and data analyses and reviewed the manuscript.

ORCID
Semira Sheikh https://orcid.org/0000-0002-5897-6378
Rawan Faramand https://orcid.org/0000-0001-7750-781X
John G. Kuruvilla https://orcid.org/0000-0002-6117-320X

REFERENCES
1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-44.
2. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
3. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arna-son J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-52.
4. Jain MD, Bachmeier CA, Phuoc VH, Chavez JC. Axicabtagene ciloleu-cel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Ther Clin Risk Manag. 2018;14:1007-17.
5. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(12):2305-21.
6. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958-71.
7. Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26-33.
8. Nair R, Drillet G, Lhomme F, Le Bras A, Michel L, Rossi J, et al. Acute leukoencephalomyelopathy and quadriaparesis after CAR T-cell ther-apy. Haematologica. 2021:106(5):1504-1506.
9. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404-19.
10. Turtle CJ, Hanafi LA, Berger C, Huidecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
11. Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, et al. Tumor microenvironment composition and severe cytokine release syn-drome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823-31.
12. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumar A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267-70.
13. Chong EA, Meelenhorst J, Svoboda J, Nasta S, Landsburg D, et al. Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy. Blood 2017;130(51):4121.
14. Jacobson CA, Westin JR, Miklos DB, Herrera AF, et al. Phase 1/2 pri-mary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cell) in combi-nation with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). In: AACR Annual Meeting. 2020.
15. Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune check-point inhibitors: Review of the literature. Eur J Cancer. 2017;73:1-8.
16. Belin C, Simard C, Dos Santos A, Ayriignac X, Berger C, Cartron G, et al. Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: a French neurological multi-center survey. Neuro-Oncology. 2019;21(S3):iii5.
17. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syn-drome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021.